TITLE:
A prospective, open label, 24-week trial of methylcobalamin in the treatment of diabetic polyneuropathy
AUTHORS:
Jacqueline C. Dominguez, Arlene R. Ng, Ludwig F. Damian
KEYWORDS:
Methylcobalamin; Diabetic Polyneuropathy; Therapeutics; Clinical Trial
JOURNAL NAME:
Journal of Diabetes Mellitus,
Vol.2 No.4,
November
27,
2012
ABSTRACT: Introduction: Vitamin B complex has been used for peripheral neuropathy for a long time and continues to be part of current practice despite lack of strong evidence for its use and its non-inclusion in treatment guidelines. Objective: To determine the clinical and neurophysiological effects of 1500 μgm/day of oral methylcobalamin among subjects with diabetic polyneuropathy. Methodology: We conducted a prospective, open-label study on adult diabetic subjects with polyneuropathy who were given 1500 μgm/day of oral methylcobalamin over 24-weeks. The primary outcome measure was the Toronto Clinical Scoring System (CSS) and secondary measures were Subjective Impression of Change, Clinicians Impression of Change and neurophysiological parameters. Results: Out of forty eight subjects, thirty seven completed treatment and twenty one agreed to have repeat neurophysiologic study post-treatment. At the end of treatment, there was a significant decline in the Toronto CSS score (p